Septerna (SEPN) stock: insider trades, news & valuation
Heavy sellingShare price and insider trades
Septerna insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 5 sold $76.1M of SEPN stock on the open market.
Get emailed when insiders cluster-buy stocks like SEPN
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
SEPN insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $72.4M | 11 |
| Q2 2026 | — | 0 | $1.5M | 11 |
| Q1 2026 | — | 0 | $2.1M | 4 |
| Q4 2025 | — | 0 | $63K | 1 |
Valuation, profit and volume
Summary
Over the past 12 months, 0 Septerna, Inc. insiders reported open-market purchases totaling $0, while 5 insiders reported sales totaling $76.1M. Among insiders with enough purchase history to measure, Rajeev M. Shah (Director) has the highest Insider Score at 90. 24 of 27 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Sep 3SEC | Daniel D. LongSvp, Drug Discovery | Sell Plan | 3,33396,412 held (−3%) | $37.83 | $126K | +1.4% | — |
| Aug 14SEC | Rajeev M. ShahDirector | Sell | 746,5004,777,415 held (−14%) | $42.50 | $31.7M | -9.7% | 90 |
| Aug 14SEC | Rajeev M. ShahDirector | Sell | 746,500725,443 held (−51%) | $42.50 | $31.7M | -9.7% | 90 |
| Aug 14SEC | Rock Ventures Gp Vi, L.p. Third10% Owner | Sell Plan | 147,0596,068,532 held (−2%) | $50.27 | $7.4M | -23.7% | — |
| Aug 14SEC | Rock Ventures Gp Vi, L.p. Third10% Owner | Sell Plan | 1416,068,391 held (−0%) | $51.08 | $7K | -24.9% | — |
| Aug 13SEC | Elizabeth BhattCOO, President | Sell Plan | 25,000174,209 held (−13%) | $44.00 | $1.1M | -12.8% | — |
| Aug 5SEC | Daniel D. LongSvp, Drug Discovery | Sell Plan | 2,33496,412 held (−2%) | $34.68 | $81K | +10.6% | — |
| Aug 5SEC | Daniel D. LongSvp, Drug Discovery | Sell Plan | 1,00098,746 held (−1%) | $33.98 | $34K | +12.9% | — |
| Jul 17SEC | Elizabeth BhattCOO, President | Sell Plan | 4,000174,209 held (−2%) | $33.99 | $136K | +12.9% | — |
| Jul 2SEC | Daniel D. LongSvp, Drug Discovery | Sell Plan | 2,10097,645 held (−2%) | $34.10 | $72K | +12.5% | — |
| Jul 2SEC | Daniel D. LongSvp, Drug Discovery | Sell Plan | 1,23396,412 held (−1%) | $34.81 | $43K | +10.2% | — |
| Jun 30SEC | Samira ShaikhlyChief People Officer | Sell Plan | 2,178793 held (−73%) | $35.18 | $77K | +9.1% | — |
| Jun 24SEC | Daniel D. LongSvp, Drug Discovery | Sell Plan | 8,000103,412 held (−7%) | $35.10 | $281K | +9.3% | — |
| Jun 24SEC | Daniel D. LongSvp, Drug Discovery | Sell Plan | 7,00096,412 held (−7%) | $35.97 | $252K | +6.7% | — |
| Jun 16SEC | Samira ShaikhlyChief People Officer | Sell Plan | 6,250793 held (−89%) | $35.08 | $219K | +9.4% | — |
| Jun 3SEC | Samira ShaikhlyChief People Officer | Sell Plan | 2,889793 held (−78%) | $29.66 | $86K | +29.4% | — |
| Jun 3SEC | Samira ShaikhlyChief People Officer | Sell Plan | 1,7005,028 held (−25%) | $27.78 | $47K | +38.1% | — |
| Jun 3SEC | Samira ShaikhlyChief People Officer | Sell Plan | 1,3463,682 held (−27%) | $28.79 | $39K | +33.3% | — |
| May 28SEC | Samira ShaikhlyChief People Officer | Sell Plan | 11,798793 held (−94%) | $30.06 | $355K | +27.6% | — |
| Apr 17SEC | Elizabeth BhattCOO, President | Sell Plan | 2,573175,636 held (−1%) | $23.76 | $61K | +61.5% | — |
| Apr 17SEC | Elizabeth BhattCOO, President | Sell Plan | 1,101174,535 held (−1%) | $25.24 | $28K | +52.0% | — |
| Apr 17SEC | Elizabeth BhattCOO, President | Sell Plan | 326174,209 held (−0%) | $25.86 | $8K | +48.4% | — |
| Mar 4SEC | Samira ShaikhlyChief People Officer | Sell Plan | 66,363793 held (−99%) | $28.14 | $1.9M | +36.4% | — |
| Mar 4SEC | Samira ShaikhlyChief People Officer | Sell Plan | 4,09067,156 held (−6%) | $27.51 | $113K | +39.5% | — |
| Feb 20SEC | Elizabeth BhattCOO, President | Sell Plan | 2,200176,009 held (−1%) | $28.46 | $63K | +34.8% | — |
| Feb 20SEC | Elizabeth BhattCOO, President | Sell Plan | 1,800174,209 held (−1%) | $29.58 | $53K | +29.7% | — |
| Nov 13SEC | Daniel D. LongSvp, Drug Discovery | Sell | 3,50192,911 held (−4%) | $18.06 | $63K | +112.5% | — |
Insiders at Septerna, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Rajeev M. ShahDirector | — | $63.5M | Aug 14, 2026 | 90 |
| Rock Ventures Gp Vi, L.p. Third10% Owner | — | $7.4M | Aug 14, 2026 | — |
| Samira ShaikhlyChief People Officer | — | $2.8M | Jun 30, 2026 | — |
| Elizabeth BhattCOO, President | — | $1.4M | Aug 13, 2026 | — |
| Daniel D. LongSvp, Drug Discovery | — | $951K | Sep 3, 2026 | — |
SEPN stock: common questions
Are Septerna, Inc. insiders buying SEPN stock?
In the past 12 months, 0 insiders reported open-market purchases of SEPN worth $0.
Are Septerna, Inc. insiders selling SEPN stock?
5 insiders reported sales worth $76.1M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is SEPN's 52-week range?
Over the past year SEPN has traded between $18.10 and $48.19. It last closed at $38.37 on Oct 9, 2026.